BIO hosted a media briefing on Wednesday, June 30th, with Jim Greenwood and Rachel King, Co-Founder and CEO of GlycoMimetics, Inc. and member of BIO’s Executive Committee.
Jim and Rachel addressed the public policies under consideration by Congress, regulatory agencies and the courts which have the potential to impact the biotechnology industry. Key discussion topics included implementation of health care reform (biosimilars, comparative effectiveness, Therapeutic Discovery Project Program, and Cures Acceleration Network), upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA) and the need to provide sufficient appropriations for FDA, and the Supreme Court’s recent ruling in Bilski v. Kappos. Jim and Rachel also discussed the importance of providing strong IP protection to promote biotech innovation and the broader impact of public policy on the biotech industry.
More than half of the briefing was dedicated to a question and answer period. Key areas of inquiry were the implementation of the biosimilars pathway, comparative effectiveness and BIO’s nominees to the Governing Board of the Patient-Centered Outcomes Research Institute, the outlook for patent reform, appropriations for Cures Acceleration Network (which was authorized but not funded by the health care reform law) and the implementation of the Therapeutic Discovery Project Program.